Role of the cGAS-STING pathway in regulating the tumor-immune microenvironment in dMMR/MSI colorectal cancer

[1]  A. Namdar,et al.  Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN–driven CCL5 and CXCL10 , 2021, The Journal of experimental medicine.

[2]  D. Tougeron,et al.  Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies , 2021, Cancers.

[3]  A. Bardelli,et al.  Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers , 2021, Cancers.

[4]  F. Salsbury,et al.  TREX1 as a Novel Immunotherapeutic Target , 2021, Frontiers in Immunology.

[5]  A. Davis,et al.  MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway. , 2020, Cancer cell.

[6]  Tao Wang,et al.  DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. , 2020, Cancer cell.

[7]  Z. Rosenwaks,et al.  Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite Instability , 2020, Cancers.

[8]  Y. Tao,et al.  cGAS/STING: novel perspectives of the classic pathway , 2020, Molecular Biomedicine.

[9]  Caicun Zhou,et al.  cGAS-STING, an important pathway in cancer immunotherapy , 2020, Journal of Hematology & Oncology.

[10]  Jing-Yuan Fang,et al.  Comprehensive review of targeted therapy for colorectal cancer. , 2020, Signal transduction and targeted therapy.

[11]  A. Jemal,et al.  Colorectal cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[12]  T. Zheng,et al.  STING: a master regulator in the cancer-immunity cycle , 2019, Molecular Cancer.

[13]  Katsuharu Saito,et al.  A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ , 2019, Oncology letters.

[14]  Yu Seong Lee,et al.  STING signaling is a potential immunotherapeutic target in colorectal cancer , 2019, Journal of Cancer.

[15]  E. Giovannucci,et al.  Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies , 2019, Nature Reviews Gastroenterology & Hepatology.

[16]  J. Luke,et al.  STING pathway agonism as a cancer therapeutic , 2019, Immunological reviews.

[17]  Z. Stadler,et al.  Immunotherapy in colorectal cancer: rationale, challenges and potential , 2019, Nature Reviews Gastroenterology & Hepatology.

[18]  L. Cantley,et al.  The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment , 2018, Cell.

[19]  K. Katakura,et al.  Glycosyltransferase Gene Expression Identifies a Poor Prognostic Colorectal Cancer Subtype Associated with Mismatch Repair Deficiency and Incomplete Glycan Synthesis , 2018, Clinical Cancer Research.

[20]  Zhijian J. Chen,et al.  The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer , 2018, The Journal of experimental medicine.

[21]  Hideo Baba,et al.  CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. , 2018, Cancer treatment reviews.

[22]  J. Mulé,et al.  Suppression of STING Signaling through Epigenetic Silencing and Missense Mutation Impedes DNA-Damage Mediated Cytokine Production , 2018, Oncogene.

[23]  J. Qin,et al.  Blockade of CCR5-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy in gastric cancer , 2018, Immunopharmacology and immunotoxicology.

[24]  K. Kaestner,et al.  Cytoplasmic chromatin triggers inflammation in senescence and cancer , 2017, Nature.

[25]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[26]  D. Nowis,et al.  STING Signaling in Cancer Cells: Important or Not? , 2017, Archivum Immunologiae et Therapiae Experimentalis.

[27]  Angelika Amon,et al.  Chromosome Mis-segregation Generates Cell-Cycle-Arrested Cells with Complex Karyotypes that Are Eliminated by the Immune System. , 2017, Developmental cell.

[28]  Yuanyuan Ruan,et al.  Decreased expression of STING predicts poor prognosis in patients with gastric cancer , 2017, Scientific Reports.

[29]  S. Elledge,et al.  Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy , 2017, Science.

[30]  Qing-an Jia,et al.  Decreased Expression of TMEM173 Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma , 2016, PloS one.

[31]  Daniel G Anderson,et al.  MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment , 2016, Nature Communications.

[32]  Haoyuan Wang,et al.  Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference , 2016, Oncotarget.

[33]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[34]  G. Barber,et al.  Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis. , 2016, Cell reports.

[35]  F. Martinon,et al.  STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity , 2015, Proceedings of the National Academy of Sciences.

[36]  Charles M. Rice,et al.  Corrigendum: A diverse range of gene products are effectors of the type I interferon antiviral response , 2015, Nature.

[37]  A. Goel,et al.  Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB+ CD8+ T-cell infiltration , 2014, Oncotarget.

[38]  A. Colombatti,et al.  The Inflammatory Chemokine CCL5 and Cancer Progression , 2014, Mediators of inflammation.

[39]  J. Lubiński,et al.  Germline deletions in the EPCAM gene as a cause of Lynch syndrome – literature review , 2013, Hereditary cancer in clinical practice.

[40]  G. Barber,et al.  STING recognition of cytoplasmic DNA instigates cellular defense. , 2013, Molecular cell.

[41]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[42]  Zhijian J. Chen,et al.  Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA , 2013, Science.

[43]  Christopher T. Jones,et al.  A diverse array of gene products are effectors of the type I interferon antiviral response , 2011, Nature.

[44]  Julie O. Culver,et al.  Recurrence and variability of germline EPCAM deletions in Lynch syndrome , 2011, Human mutation.

[45]  Colin C Pritchard,et al.  Colorectal cancer molecular biology moves into clinical practice , 2010, Gut.

[46]  A. de la Chapelle,et al.  Clinical relevance of microsatellite instability in colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Ajay Goel,et al.  Microsatellite instability in colorectal cancer. , 2010, Gastroenterology.

[48]  S. Bustin,et al.  Tumour‐infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic , 2004, The British journal of surgery.

[49]  Robert H. Silverman,et al.  Activation of the interferon system by short-interfering RNAs , 2003, Nature Cell Biology.